Physician profile
Derrick W Walker
NPI 1760611529
$3,470.01
in general payments reported to CMS, 2019-2025
29 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.26 · 2021: $136 · 2022: $340 · 2023: $674 · 2024: $1,244 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,968.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $834.84 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $572.20 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $510.16 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $209.64 | 2022-2025 | |
| Astellas Pharma US INC | $174.51 | 2024-2025 | Veozah |
| Abbvie INC. | $142.28 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $112.93 | 2024-2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.46 | 2024-2025 | Jardiance |
| Axsome Therapeutics, INC. | $96.32 | 2024-2025 | Auvelity |
| Amgen INC. | $87.62 | 2022-2025 | Evenity, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $73.39 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $71.70 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.91 | 2022-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $47.79 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.77 | 2023 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $47.24 | 2023-2024 | Yupelri |
| Dynavax Technologies Corporation | $38.74 | 2023-2025 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $30.19 | 2024-2025 | Trintellix |
| Exact Sciences Corporation | $28.68 | 2025 | The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $26.33 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $22.85 | 2022 | |
| Neurocrine Biosciences, INC. | $22.41 | 2024 | Ingrezza |
| Corium, LLC | $17.41 | 2023 | Azstarys |
| Tempus Ai, INC | $16.96 | 2024 | |
| Shield Therapeutics INC | $15.04 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.01 | 2024 | Zoryve |
| Abbott Laboratories | $14.83 | 2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $12.91 | 2022 | |
| Kaleo, INC. | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.